+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alpha-1 Antitrypsin Drugs - Global Market Trajectory & Analytics

  • ID: 5309396
  • Report
  • April 2021
  • Region: Global
  • 105 pages
  • Global Industry Analysts, Inc
Global Alpha-1 Antitrypsin Drugs Market to Reach $2 Billion by 2027

Amid the COVID-19 crisis, the global market for Alpha-1 Antitrypsin Drugs estimated at US$1.1 Billion in the year 2020, is projected to reach a revised size of US$2 Billion by 2027, growing at a CAGR of 9.6% over the period 2020-2027.



The U.S. Market is Estimated at $319.3 Million, While China is Forecast to Grow at 9% CAGR

The Alpha-1 Antitrypsin Drugs market in the U.S. is estimated at US$319.3 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$354.1 Million by the year 2027 trailing a CAGR of 9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.9% and 7.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Select Competitors (Total 43 Featured):
  • Abeona Therapeutics
  • Alnylam Pharmaceuticals
  • Applied Genetic Technologies Corp
  • Arrowhead Research Corporation
  • Baxalta
  • Baxter
  • CSL Behring
  • Grifols
  • Kamada
  • Shire
  • Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Alpha-1 Antitrypsin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Alpha-1 Antitrypsin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • Table 4: USA Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 5: USA Historic Review for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 6: Canada Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 7: Canada Historic Review for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 8: Japan Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 9: Japan Historic Review for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 10: China Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 11: China Historic Review for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 12: Europe Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 13: Europe Historic Review for Alpha-1 Antitrypsin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 14: Europe 15-Year Perspective for Alpha-1 Antitrypsin Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 15: France Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 16: France Historic Review for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 17: Germany Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 18: Germany Historic Review for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 19: Italy Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 20: Italy Historic Review for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 21: UK Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 22: UK Historic Review for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 23: Rest of Europe Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 24: Rest of Europe Historic Review for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 25: Asia-Pacific Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 26: Asia-Pacific Historic Review for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 27: Rest of World Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 28: Rest of World Historic Review for Alpha-1 Antitrypsin Drugs by Segment - Alpha-1 Antitrypsin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
IV. COMPETITION
  • Total Companies Profiled: 43
Note: Product cover images may vary from those shown
Adroll
adroll